Galecto, Inc., a leading developer of novel treatments for fibrosis and cancer, today announces the appointment of the highly experienced industry leader Bertil Lindmark as Chief Medical Officer per February 1, 2020.
About Susan Tantawi
This author has yet to write their bio.Meanwhile lets just say that we are proud Susan Tantawi contributed a whooping 4 entries.
Entries by Susan Tantawi
Galecto Biotech and PharmAkea, two clinical-stage pharmaceutical companies with robust pipelines in fibrotic diseases and cancer, have merged into a single company.
Galecto is set to merge with PharmAkea. The deal will see Denmark’s Galecto incorporate in the U.S. and add a clinical-phase treatment for idiopathic pulmonary fibrosis (IPF) to its pipeline.
Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and cancer, and PharmAkea, Inc., a privately held San Diego-based pharmaceutical company developing novel small molecules against protein targets involved in fibroproliferative disease, today announced the two companies will merge.